Medscape4d
T-DXd Shows Consistent Benefit Across Endocrine-Resistant HR+/HER2-Low Breast Cancer Subgroups
New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...
Hosted on MSN9d
Better Quality of Life With RT vs Endocrine Therapy in Older Breast Cancer Patients
At 24 months, endocrine therapy appeared to have a more negative effect on HRQOL as measured by the global health status (GHS ...
Some Early Forms of Breast Cancer May Not Need Treatment, Study Says
B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...
Targeted Oncology9d
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer ...
Cure Today10d
Ultra-Sensitive ctDNA Testing Can Detect ctDNA in HR+ Breast Cancer
Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.
Targeted Oncology9d
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced ...
Medscape4d
Can AI Tool Guide CDK4/6 Inhibitor Use in Breast Cancer?
A machine learning tool incorporating both clinical and genomic data helps predict response to CDK4/6 inhibitor therapy in ...